- Home
- BTBD vs SBFM Comparison
BTBD vs SBFM Comparison
Compare BTBD & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTBD
- SBFM
- Stock Information
- Founded
- BTBD 1987
- SBFM 2006
- Country
- BTBD United States
- SBFM United States
- Employees
- BTBD N/A
- SBFM N/A
- Industry
- BTBD Restaurants
- SBFM Biotechnology: Pharmaceutical Preparations
- Sector
- BTBD Consumer Discretionary
- SBFM Health Care
- Exchange
- BTBD Nasdaq
- SBFM Nasdaq
- Market Cap
- BTBD 6.6M
- SBFM 7.7M
- IPO Year
- BTBD 2021
- SBFM N/A
- Fundamental
- Price
- BTBD $1.34
- SBFM $1.45
- Analyst Decision
- BTBD
- SBFM Strong Buy
- Analyst Count
- BTBD 0
- SBFM 1
- Target Price
- BTBD N/A
- SBFM $15.00
- AVG Volume (30 Days)
- BTBD 1.3K
- SBFM 84.3K
- Earning Date
- BTBD 08-12-2025
- SBFM 08-15-2025
- Dividend Yield
- BTBD N/A
- SBFM N/A
- EPS Growth
- BTBD N/A
- SBFM N/A
- EPS
- BTBD N/A
- SBFM N/A
- Revenue
- BTBD $14,864,398.00
- SBFM $36,234,578.00
- Revenue This Year
- BTBD N/A
- SBFM $192.48
- Revenue Next Year
- BTBD N/A
- SBFM N/A
- P/E Ratio
- BTBD N/A
- SBFM N/A
- Revenue Growth
- BTBD 4.71
- SBFM 35.51
- 52 Week Low
- BTBD $1.00
- SBFM $1.17
- 52 Week High
- BTBD $2.02
- SBFM $8.78
- Technical
- Relative Strength Index (RSI)
- BTBD 50.71
- SBFM 48.48
- Support Level
- BTBD $1.28
- SBFM $1.41
- Resistance Level
- BTBD $1.36
- SBFM $1.58
- Average True Range (ATR)
- BTBD 0.03
- SBFM 0.12
- MACD
- BTBD -0.01
- SBFM -0.01
- Stochastic Oscillator
- BTBD 41.18
- SBFM 18.91
About BTBD BT Brands Inc.
BT Brands Inc operates and owns a fast-food restaurant called Burger Time. The company also operates in Minnesota as a franchisee of Dairy Queen. It offers a variety of burgers and other affordably priced foods such as chicken sandwiches, pulled pork sandwiches, chicken chunks, side dishes, and soft drinks.
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.